Psoriatic Arthritis Therapeutics Drug

Psoriatic Arthritis Therapeutics Drug Market Outlook

The global Psoriatic Arthritis Therapeutics Drug Market is projected to reach approximately USD 14.5 billion by 2035, growing at a compound annual growth rate (CAGR) of around 7.2% during the forecast period from 2025 to 2035. The increasing prevalence of psoriatic arthritis, driven by rising obesity rates, sedentary lifestyles, and genetic factors, is a significant growth factor. Moreover, the growing awareness of psoriatic arthritis, coupled with advancements in drug development and a surge in healthcare expenditure, further supports the market’s expansion. Enhanced research in chronic inflammatory diseases and the availability of novel pharmaceutical therapies are anticipated to fuel market growth. Additionally, the rise in the aging population, who are more susceptible to developing psoriatic arthritis, has created a heightened demand for effective therapeutic solutions.

Growth Factor of the Market

One of the primary growth factors driving the psoriatic arthritis therapeutics drug market is the increasing investment in research and development (R&D) for targeted therapies, which have shown promising results in clinical trials. This focus on innovation not only enhances treatment efficacy but also improves patient adherence to therapy, thus expanding the market. Furthermore, regulatory approvals for new drugs and biologics that target specific pathways in psoriatic arthritis are creating an environment conducive to growth. An increasing number of collaborative efforts between pharmaceutical companies and research institutions are accelerating the pace of discovery and development of new therapeutic options. The rise in personalized medicine, which tailors treatment to individual patients based on their genetic makeup and disease characteristics, also represents a significant opportunity for market growth. Lastly, the growing digital health landscape, including telemedicine and health apps, is facilitating better patient management and engagement, indirectly propelling the market forward.

Key Highlights of the Market

• Increased prevalence of psoriatic arthritis driving demand for effective therapeutics.
• Rising investments in R&D for novel drug development and targeted therapies.
• Growing awareness of psoriatic arthritis among healthcare professionals and patients.
• Expansion of distribution channels, including online pharmacies, improving accessibility.
• Innovations in biologics and personalized care options leading market growth.

By Drug Type

Nonsteroidal Anti-Inflammatory Drugs

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) play a pivotal role in the management of psoriatic arthritis, primarily by alleviating pain, reducing inflammation, and improving overall joint function. These medications are often the first line of treatment prescribed to patients due to their effectiveness in managing mild to moderate symptoms. The growing acceptance of NSAIDs is attributed to their relatively low cost and broad availability, making them accessible to a large patient population. Furthermore, ongoing advancements in formulation and delivery methods are enhancing the efficacy and tolerability of these drugs. Though they are effective, the long-term use of NSAIDs is often associated with gastrointestinal side effects, which necessitates careful monitoring and patient counseling during treatment.

Disease Modifying Antirheumatic Drugs

Disease Modifying Antirheumatic Drugs (DMARDs) are crucial for the treatment of psoriatic arthritis as they aim to slow the progression of the disease and prevent joint damage. Traditional DMARDs such as methotrexate have been widely used, but there has been a noticeable shift towards newer biologic DMARDs that target specific pathways involved in the inflammatory process. The growing evidence supporting the benefits of DMARDs in improving long-term outcomes for patients with psoriatic arthritis has significantly bolstered their acceptance among healthcare providers. As the understanding of psoriatic arthritis continues to evolve, the introduction of new DMARDs that provide enhanced efficacy and fewer side effects is expected to drive market growth further.

Biologics

Biologics have revolutionized the treatment landscape for psoriatic arthritis, offering targeted therapy options that significantly improve patient outcomes. Agents such as TNF inhibitors, IL-17 inhibitors, and IL-12/23 inhibitors fall into this category and are known for their ability to modify the underlying disease rather than just alleviating symptoms. The increasing prevalence of psoriatic arthritis and the growing patient population are contributing to the rising demand for biologics. Additionally, advances in biotechnology have led to the development of newer biologics with improved efficacy profiles and reduced immunogenicity. The high cost associated with biologics, however, poses a challenge to market penetration, yet ongoing efforts in pricing strategies and reimbursement policies are expected to mitigate this issue.

Corticosteroids

Corticosteroids are used in the treatment of psoriatic arthritis due to their potent anti-inflammatory effects. These drugs can provide rapid relief from the inflammation and pain associated with flare-ups of the disease. However, they are generally recommended for short-term use because of the potential for serious side effects with long-term administration, including osteoporosis and increased risk of infections. Their role in therapy is often as an adjunct to other, longer-term treatment modalities. Recent clinical studies have shown that corticosteroids can effectively manage acute exacerbations when used judiciously alongside DMARDs or biologics, leading to a nuanced approach in managing psoriatic arthritis.

Others

The category of "Others" includes various alternative and adjunctive medications that may be utilized in the management of psoriatic arthritis. This can encompass topical treatments, physical therapy options, and emerging therapies that are still undergoing clinical trials. Topical treatments are particularly beneficial for patients with skin symptoms associated with psoriasis, as they provide localized relief without the systemic effects of oral or injectable medications. The ongoing exploration of combination therapies and integrative approaches in the treatment of psoriatic arthritis indicates that this segment may grow as patients and clinicians seek comprehensive management strategies.

By Route of Administration

Oral

The oral route of administration is the most common method for delivering medications to patients with psoriatic arthritis. Oral medications, including NSAIDs and DMARDs, offer patients convenience and ease of use, which are critical factors in adherence to therapy. The market for oral administration is supported by the wide acceptance of oral formulations and the ongoing development of new oral agents that show improved efficacy and safety profiles. Furthermore, the ability to self-administer oral medications adds to the attractiveness of this route, as it allows patients to manage their treatment without the need for regular healthcare visits. As the research progresses, oral therapies, especially those that target specific pathways in the disease, are expected to dominate this segment.

Injectable

Injectable medications, including biologics and corticosteroids, are becoming increasingly popular in the treatment of psoriatic arthritis due to their ability to deliver medications directly into the bloodstream, ensuring faster and more effective action. Injectables can be administered in a clinical setting or self-administered by patients at home, providing a degree of flexibility. This route is particularly vital for biologics, which often require injection due to their molecular weight and instability in oral formulations. The growth of this segment is also attributed to advancements in the development of auto-injector devices that enhance usability and patient comfort. The increasing shift towards injectable therapies reflects the broader trend of personalized medicine, as these treatments can be tailored to meet individual patient needs and responses.

Topical

Topical medications serve as an essential route of administration for patients suffering from psoriatic arthritis, particularly for those with skin lesions associated with psoriasis. These treatments allow for localized application and can effectively reduce symptoms without systemic exposure. Topical therapies are often used in conjunction with systemic treatments, providing a comprehensive management approach. In recent years, there has been a surge in the development of topical agents that contain active ingredients aimed at not just skin symptoms but also underlying joint inflammation. As the focus on patient-centered care continues to grow, the topical route offers a viable option for patients looking for targeted relief with fewer systemic side effects.

Others

The "Others" category in the route of administration segment encompasses emerging methods of drug delivery that are currently under investigation or in the early stages of market introduction. This may include transdermal patches, inhalable formulations, or localized delivery systems being developed to enhance drug absorption and efficacy. While these routes are not yet mainstream, they hold potential for future applications in psoriatic arthritis therapy as researchers seek to improve patient compliance and accessibility. Innovations in drug delivery technologies are expected to pave the way for more patient-friendly options that could change the treatment landscape in the coming years.

By Distribution Channel

Hospital Pharmacies

Hospital pharmacies play a critical role in the distribution of psoriatic arthritis therapeutics, particularly for acute care patients who require immediate access to medications. These pharmacies are particularly important for administering injectable biologics and other advanced therapies that may require specialized storage and handling. The close collaboration between healthcare providers and hospital pharmacies ensures that patients receive timely and appropriate medications as part of their comprehensive treatment plan. As healthcare systems continue to evolve and integrate more specialized care services, the reliance on hospital pharmacies for psoriatic arthritis therapeutics is expected to grow, supporting the overall market.

Retail Pharmacies

Retail pharmacies are pivotal in providing access to psoriatic arthritis treatments, especially for patients who prefer to manage their conditions through outpatient settings. These pharmacies offer convenience and can often provide a wide range of therapeutic options, including oral medications, topical treatments, and even some biologics that can be administered at home. The increasing trend of patient engagement in managing chronic diseases has bolstered the role of retail pharmacies, as they often serve as a point of contact for patients seeking advice and information about their medications. As the market expands, retail pharmacies are likely to enhance their services to offer better patient support and education regarding psoriatic arthritis therapies.

Online Pharmacies

The rise of online pharmacies has transformed the distribution landscape for psoriatic arthritis therapeutics, particularly in the wake of the COVID-19 pandemic, which accelerated the adoption of digital health solutions. Online pharmacies provide patients with the convenience of ordering medications from the comfort of their homes, offering a broader selection of products, often at competitive prices. This channel not only improves access for patients in remote or underserved areas but also allows for discreet purchasing of medications that may be stigmatized. As regulations around online pharmaceutical sales continue to evolve, the market for online pharmacies is expected to expand, providing additional opportunities for patients to obtain psoriatic arthritis therapies.

Others

The "Others" category in the distribution channel segment includes alternative dispensing options such as specialty pharmacies and direct-to-patient programs offered by pharmaceutical companies. Specialty pharmacies focus on delivering high-cost medications, such as biologics, that require specific expertise in handling and patient management. These pharmacies often provide additional services such as medication management, adherence support, and education about disease management. Direct-to-patient programs, on the other hand, are gaining traction as manufacturers seek to ensure that patients have access to their medications through innovative delivery methods. As healthcare continues to evolve, these distribution channels will play increasingly important roles in meeting the diverse needs of patients with psoriatic arthritis.

By Mechanism of Action

TNF Inhibitors

TNF inhibitors are among the most widely used biologic therapies for treating psoriatic arthritis, targeting tumor necrosis factor (TNF), a key mediator in the inflammatory process associated with the disease. By blocking TNF, these inhibitors can significantly reduce inflammation, alleviate pain, and improve joint function in patients. The efficacy of TNF inhibitors has led to their widespread adoption, with several agents currently available on the market. Ongoing research continues to explore the long-term benefits and safety profiles of these medications, contributing to their strong presence in the psoriatic arthritis therapeutics market. Additionally, the development of biosimilars is expected to enhance accessibility and affordability for patients requiring TNF inhibitor therapy.

IL-17 Inhibitors

IL-17 inhibitors have emerged as a revolutionary class of therapies for psoriatic arthritis, specifically targeting interleukin-17 (IL-17), a cytokine that plays a pivotal role in the inflammatory response. By inhibiting IL-17, these drugs help to address not only joint inflammation but also the skin symptoms associated with psoriasis. The rapid growth of IL-17 inhibitors in the market is attributed to their favorable efficacy and safety profiles observed in clinical trials, leading to substantial improvements in both joint and skin conditions for patients. As awareness of the therapeutic potential of IL-17 inhibitors grows, they are becoming a vital component of treatment regimens for psoriatic arthritis.

JAK Inhibitors

Janus kinase (JAK) inhibitors represent a novel approach to treating psoriatic arthritis by blocking specific enzymes involved in the inflammatory process. These oral medications offer the advantage of convenient administration and have demonstrated significant efficacy in reducing disease activity and improving quality of life for patients. The flexibility of JAK inhibitors, combined with their rapid onset of action, has positioned them as an attractive option for many healthcare providers. As ongoing clinical studies continue to support their safety and efficacy, JAK inhibitors are likely to gain prominence in the psoriatic arthritis therapeutics market, particularly among patients who may not respond well to traditional therapies.

PDE4 Inhibitors

Phosphodiesterase-4 (PDE4) inhibitors are a relatively new class of oral medications that target the inflammatory pathways in psoriatic arthritis. By inhibiting the PDE4 enzyme, these agents help to modulate the immune response, thereby reducing inflammation and improving symptoms. The growing body of clinical evidence supporting the efficacy of PDE4 inhibitors has led to their increasing acceptance in the therapeutic landscape. While they are not as widely used as biologics, PDE4 inhibitors provide an alternative option for patients, particularly those who prefer oral therapies. As awareness of their benefits continues to expand, they are expected to carve out an important niche in the psoriatic arthritis market.

Others

The "Others" category in the mechanism of action segment includes various emerging therapies and investigational drugs that target different inflammatory pathways associated with psoriatic arthritis. These may involve novel approaches such as targeting other interleukins or immune modulators that influence the disease process. As ongoing research and clinical trials continue to explore these new mechanisms, the potential for innovative treatments that may offer enhanced efficacy and safety profiles is promising. The diversification of treatment options will contribute to a more robust psoriatic arthritis therapeutics market, catering to the needs of a varied patient population.

By Region

The North America region is the largest market for psoriatic arthritis therapeutics, accounting for a significant share of the global revenue. The increase in the prevalence of psoriatic arthritis, combined with enhanced awareness among healthcare professionals and patients, has driven demand in this region. The strong presence of major pharmaceutical companies and ongoing investments in R&D further bolster the market. In addition, favorable reimbursement policies and access to advanced medical technologies are contributing to the growth of this market segment. The North American psoriatic arthritis therapeutics drug market is projected to grow at a CAGR of around 7.5% over the forecast period, reflecting positive trends in treatment adoption and therapeutic innovation.

Europe stands as another key market for psoriatic arthritis therapeutics, driven by the increasing prevalence of autoimmune diseases and a growing aging population susceptible to such conditions. The European market is characterized by a diverse range of treatment options available for patients, including innovative biologics and DMARDs. Additionally, the region is witnessing significant investments in healthcare infrastructure and emphasis on research initiatives focusing on chronic inflammatory diseases. The European psoriatic arthritis therapeutics market is expected to grow steadily, contributing to the overall growth of the global market as new therapies continue to emerge and gain regulatory approval.

Opportunities

The psoriatic arthritis therapeutics market presents numerous opportunities for growth, particularly in the realm of drug development and personalized medicine. As researchers continue to uncover the underlying mechanisms of psoriatic arthritis, there is an increasing potential for innovative therapies that can target specific patient populations. The emergence of biosimilars also opens up new avenues for market expansion, as they provide more affordable options for patients who require biologic therapies. Furthermore, as patient awareness and education improve, more individuals are seeking treatment, leading to increased market demand. Collaborative efforts between pharmaceutical companies and healthcare providers can further enhance the development and delivery of effective therapies, contributing to improved patient outcomes and greater overall market growth.

Another significant opportunity lies in the integration of digital health technologies into psoriatic arthritis management. Telemedicine and mobile health applications are gaining traction, allowing patients to engage more actively in their treatment plans and monitor their health outcomes conveniently. This shift not only enhances patient satisfaction but also encourages adherence to prescribed therapies. Additionally, as healthcare systems focus more on value-based care, there is a greater emphasis on optimizing treatment protocols and ensuring that patients receive the most effective therapies. This paradigm shift presents an opportunity for drug manufacturers to position their products as part of comprehensive management strategies, aligning with patient needs and healthcare provider goals.

Threats

Despite the promising growth prospects, the psoriatic arthritis therapeutics market faces several threats that may hinder its expansion. One of the primary concerns is the high cost associated with biologics and advanced therapies, which can limit patient access and adherence to treatment. Insurance coverage and reimbursement policies may vary significantly across regions, creating disparities in treatment availability. Additionally, the introduction of new competitors and generic alternatives can lead to market saturation, resulting in price wars that may adversely affect revenues. The evolving regulatory landscape and potential for stringent oversight of drug approval processes can also create challenges for pharmaceutical companies seeking to bring new therapies to market.

Moreover, the market is confronted with significant competition from alternative therapies and natural remedies that patients may prefer over traditional drug treatments. The rise of complementary and alternative medicine trends could divert patients from conventional therapies, impacting overall market growth. Finally, the economic uncertainties and budget constraints in healthcare systems worldwide may influence the prioritization of psoriatic arthritis treatment, potentially leading to reduced investments in research and development, and negatively impacting the availability of innovative therapies. Addressing these threats will require strategic planning, investment, and collaboration across the healthcare ecosystem.

Competitor Outlook

• AbbVie Inc.
• Amgen Inc.
• Johnson & Johnson
• Pfizer Inc.
• Bristol-Myers Squibb
• Novartis AG
• Merck & Co., Inc.
• UCB S.A.
• Gilead Sciences, Inc.
• Sanofi S.A.
• Regeneron Pharmaceuticals, Inc.
• Celgene Corporation
• Roche Holding AG
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.

The competitive landscape of the psoriatic arthritis therapeutics market is characterized by a diverse array of pharmaceutical companies, ranging from large multinational corporations to specialized biotechnology firms. Major players, such as AbbVie, Amgen, and Johnson & Johnson, have established a strong foothold in the market with their extensive portfolios of biologics and DMARDs effectively addressing psoriatic arthritis. These companies are significantly investing in R&D to develop next-generation therapies that promise improved efficacy and safety profiles to meet the evolving needs of patients. The competitive environment is also marked by collaborations and partnerships aimed at leveraging innovative technologies and research capabilities to accelerate drug development.

AbbVie, known for its blockbuster drug, Humira, has consistently focused on expanding its product offerings for psoriatic arthritis through rigorous clinical trials and investigational therapies. The company’s strong commitment to research in immunology has positioned it as a leader in biologic therapies. Similarly, Amgen has made significant strides with its IL-17 inhibitors, which have been well received in the market. The continuous pursuit of advancements in treatment options and patient engagement strategies reflects the competitive nature of this landscape, as companies aim to differentiate their products and capture market share.

Furthermore, the rise of biosimilars has started to reshape the competitive dynamics within the psoriatic arthritis therapeutics market. Companies like Pfizer and Sandoz are actively launching biosimilars, making it essential for established players to adapt their strategies to maintain market leadership. The presence of new entrants and innovative companies has intensified competition, driving down prices and enhancing accessibility to therapies for patients. As the market continues to evolve, agility and responsiveness will be crucial for companies to stay ahead of the competition and align with the changing preferences of patients and healthcare providers.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 UCB S.A.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Amgen Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AbbVie Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Novartis AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Pfizer Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Sanofi S.A.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Roche Holding AG
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Johnson & Johnson
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Merck & Co., Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Celgene Corporation
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Bristol-Myers Squibb
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Eli Lilly and Company
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Gilead Sciences, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Regeneron Pharmaceuticals, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Psoriatic Arthritis Therapeutics Drug Market, By Drug Type
    • 6.1.1 Nonsteroidal Anti-Inflammatory Drugs
    • 6.1.2 Disease Modifying Antirheumatic Drugs
    • 6.1.3 Biologics
    • 6.1.4 Corticosteroids
    • 6.1.5 Others
  • 6.2 Psoriatic Arthritis Therapeutics Drug Market, By Distribution Channel
    • 6.2.1 Hospital Pharmacies
    • 6.2.2 Retail Pharmacies
    • 6.2.3 Online Pharmacies
    • 6.2.4 Others
  • 6.3 Psoriatic Arthritis Therapeutics Drug Market, By Route of Administration
    • 6.3.1 Oral
    • 6.3.2 Injectable
    • 6.3.3 Topical
    • 6.3.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Psoriatic Arthritis Therapeutics Drug Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Psoriatic Arthritis Therapeutics Drug market is categorized based on

By Drug Type

• Nonsteroidal Anti-Inflammatory Drugs
• Disease Modifying Antirheumatic Drugs
• Biologics
• Corticosteroids
• Others

By Route of Administration

• Oral
• Injectable
• Topical
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• AbbVie Inc.
• Amgen Inc.
• Johnson & Johnson
• Pfizer Inc.
• Bristol-Myers Squibb
• Novartis AG
• Merck & Co., Inc.
• UCB S.A.
• Gilead Sciences, Inc.
• Sanofi S.A.
• Regeneron Pharmaceuticals, Inc.
• Celgene Corporation
• Roche Holding AG
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.